ManagementManagementManagementManagement
  • About LIXTE
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
  • About LIXTE
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
    • Investor Alerts
menu toggle
Close
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Dec 01, 2020 12:30pm EST

Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq

Nov 25, 2020 8:30am EST

Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split

Aug 18, 2020 9:35am EDT

The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome

Jul 21, 2020 9:35am EDT

Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer

Apr 30, 2020 10:30am EDT

Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors

Dec 04, 2019 9:35am EST

First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors

Aug 06, 2019 9:35am EDT

The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas

Jul 18, 2019 9:35am EDT

First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome

Jun 25, 2019 9:35am EDT

Lixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder

May 15, 2019 9:35am EDT

Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Contact

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
info@lixte.com

LIXTE Biotechnology Holdings, Inc. is publicly traded as LIXT.

About LIXTE

  • About LIXTE
  • Management
  • Board of Directors
  • Forward-Looking Statements

Development

  • Product Development

Publications

  • Publications

Investor Information

  • Investor Information
  • Email Alerts
Back to top
© 2023 LIXTE Biotechnology Holdings, Inc. (LIXTE). All Rights Reserved. Site by Third Eye Industries
    Close